Qure NV (QURE) reports significant progress in Huntington's disease treatment but faces hurdles with FDA approval.

Management stated that the timing of the BLA submission for AMT-130 is now uncertain following recent FDA feedback. Kapusta explained, "the latest FDA feedback is certainly surprising and ...

Although amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). are very different diseases, they have ...

Larimar Therapeutics finds itself navigating a complex landscape of groundbreaking clinical progress against a backdrop of mounting financial pressures. The company's lead drug candidate, nomlabofusp, ...

Cash and cash equivalents decreased 4% to $54.3 million at September 30, 2025 as compared to the fiscal year-ended June 30, 2025.Total Revenues - Net increased by 4% to $26.0 million for the quarter e ...

Electroencephalography (EEG) has evolved from a basic investigative tool in neurophysiology to a valuable instrument in Alzheimer’s disease (AD) research ...